提醒成功
搜索
| 产品规范 | |
|---|---|
| Type | In Vivo - Reseach Grade Antibody |
| Host | CHO cells |
| catalog# | B00065 |
| Application | Flow cytometry, animal model study |
| Aliases | Nerve Growth Factor |
| Size/Concentration | 1mg/5mg/20mg |
| Isotype | Human IgG2 kappa |
| Storage | Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Human NGF |
| Formulation | PBS, pH 7.4 |
Description |
|---|
What is tanezumab biosimilar research grade? Tanezumab is a humanized IgG2-kappa monoclonal antibody against nerve growth factor (NGF) as a treatment for pain via a novel mechanisms different from conventional pain-killer drugs. NGF levels increase in the body as a result of injury, inflammation or in chronic pain states. Tanezumab selectively targets, binds to, and inhibits NGF. Tanezumab acts in the periphery in a different manner than opioids and other analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs), and in studies to date, tanezumab has not demonstrated a risk of addiction, misuse or dependence. Tanezumab biosimilar uses the same protein sequences as the therapeutic antibody tanezumab. |
Tanezumab Biosimilar, Human NGF Monoclonal Antibody B00065
规格:
- 1mg
- 5mg
- 20mg
数量:
-
+
说明书:
¥2275
-
咨询
-
收藏

微信/QQ登录


首页